Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $41.3852W HIGH $105.65
Volume
13.04 M
Value Traded
958.40 M
Short % Float
3.23%
+0.78%Week
-0.86%1 Month
-4.3%3 Month
-32.37%6 Month
+37.11%5 Year
+1,259.53%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
61.93 B
EPS (TTM)
2.53
P/E Ratio
16.88
Ent. Value
61.39 B
Total Shares
1.45 B
Float Shares
1.44 B
Insiders
0.65%
Institutions
95.12%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BSX Catalyst Timeline
Dated clinical, regulatory and corporate events for Boston Scientific Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Boston Scientific Corporation
1671Total events
8Upcoming
609Tier-1 (high impact)
2009 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationPresentation
Late-breaking data at Heart Rhythm 2026: AVANT GUARD met all endpoints, superiority over anti-arrhythmic drugs
persistent atrial fibrillationsource ↗
▲Trial InitiationTrial
Commenced enrollment in pivotal FARADIGM trial
paroxysmal and persistent atrial fibrillationsource ↗
▲Oral PresentationPresentation
FRACTURE trial met primary endpoints with SEISMIQ 4CE
severely calcified coronary artery diseasesource ↗
▲Primary Endpoint MetClinical Data
AVANT GUARD met all safety and effectiveness endpoints
persistent atrial fibrillationsource ↗
▲Primary Endpoint MetClinical Data
ELEVATE-PF demonstrated strong lesion durability
paroxysmal and persistent atrial fibrillationsource ↗
▲FDA ApprovalFDA Decision
Received FDA 510(k) clearance for TruSelect 2.6 Microcatheter
embolization proceduressource ↗
▲Oral PresentationPresentation
AVANT GUARD study met all safety and effectiveness endpoints
persistent atrial fibrillationsource ↗
▲Oral PresentationPresentation
ELEVATE-PF feasibility study demonstrated strong lesion durability
paroxysmal and persistent atrial fibrillationsource ↗
●Quarterly UpdateCorporate
Q3 2026 guidance: net sales growth ~3-5% reported and organic; adjusted EPS $0.80-$0.82
◆Oral PresentationPresentation
Participation in Bernstein's 42nd Annual Strategic Decisions Conference
▲Primary Endpoint MetClinical Data
FRACTURE IDE trial meets primary safety and effectiveness endpoints
severely calcified coronary artery diseasesource ↗
●Oral PresentationPresentation
Late-breaking data presented at EuroPCR 2026 congress
severely calcified coronary artery diseasesource ↗
▲Partnership / LicenseCorporate
Boston Scientific invests $1.5B for 34% equity stake in MiRus LLC with exclusive option to acquire SIEGEL TAVR system
▲Primary Endpoint MetFARAPULSEClinical Data
AVANT GUARD trial met all safety and effectiveness endpoints; PFA superior to AADs
persistent atrial fibrillationsource ↗
◆Full ResultsFARAPULSEClinical Data
AVANT GUARD results published in The New England Journal of Medicine
persistent atrial fibrillationsource ↗
◆Topline ReadoutFARAFLEXClinical Data
ELEVATE-PF feasibility study interim data presented
paroxysmal and persistent atrial fibrillationsource ↗
▲Subgroup AnalysisClinical Data
CHAMPION-AF sub-analysis by prior ablation status
non-valvular atrial fibrillationsource ↗
▲Long Term DataWATCHMANApprovedClinical Data
ASAP-TOO 5-year follow-up data
non-valvular atrial fibrillationsource ↗
▲Primary Endpoint MetClinical Data
PRAETORIAN DFT study met primary endpoint; non-inferiority of omitting defibrillation testing
ventricular arrhythmiasource ↗
▲Primary Endpoint MetClinical Data
CHAMPION-AF met all primary and secondary endpoints; superior bleeding risk reduction vs oral anticoagulants
non-valvular atrial fibrillation (AF) for stroke risk reductionsource ↗
▲Primary Endpoint MetEKOSApprovedClinical Data
HI-PEITHO demonstrated superiority of EKOS plus anticoagulation vs anticoagulation alone
acute pulmonary embolism (intermediate-risk)source ↗
▲Full ResultsFARAPULSEClinical Data
ADVENT Long-Term Outcomes: greater AF treatment success, fewer interventions, lower repeat ablation at 4 years vs thermal ablation
atrial fibrillationsource ↗
▲NMPA NDA ApprovalEx-US Regulatory
NMPA approval in China for OPAL HDx Mapping System
catheter visualization during FARAPULSE PFA proceduressource ↗
▲Full ResultsClinical Data
24-month COMFORT trial: durable pain relief and improved quality of life vs conventional medical management
chronic painsource ↗
▲FDA Filing AcceptedAsurysFiledRegulatory Filing
FDA 510(k) clearance for Asurys Fluid Management System
irrigation management during endoscopic urologic proceduressource ↗
▲AcquiredCorporate
Acquisition of Valencia Technologies (eCoin System) completed
urge urinary incontinencesource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA 510(k) clearance for Asurys Fluid Management System
endoscopic urologic procedures (ureteroscopy, cystoscopy, PCNL, BPH)source ↗
▲Product LaunchPost-Market
Limited market release of Asurys Fluid Management System in the U.S.
endoscopic urologic proceduressource ↗
▲Primary Endpoint MetClinical Data
HI-PEITHO trial met composite primary endpoint; EKOS plus anticoagulation superior to anticoagulation alone
acute pulmonary embolismsource ↗
●Oral PresentationPresentation
Late-breaking findings presented at ACC.26
acute pulmonary embolismsource ↗
●PublicationPresentation
Simultaneously published in The New England Journal of Medicine
acute pulmonary embolismsource ↗
▲Primary Endpoint MetClinical Data
CHAMPION-AF met all primary and secondary safety and efficacy endpoints
non-valvular atrial fibrillationsource ↗
●Oral PresentationPresentation
Late-breaking clinical trial presentation at ACC.26
non-valvular atrial fibrillationsource ↗
●PublicationPresentation
Simultaneous publication in The New England Journal of Medicine
non-valvular atrial fibrillationsource ↗
▲Quarterly UpdateCorporate
Boston Scientific reports FY2025 net sales of $20.074B, GAAP EPS $1.94, adjusted EPS $3.06
◆Oral PresentationPresentation
Participation in 44th Annual J.P. Morgan Healthcare Conference
◆AcquisitionCorporate
Boston Scientific announces agreement to acquire Valencia Technologies Corporation
overactive bladdersource ↗
▲Trial InitiationSIEGELTrial
MiRus initiated STAR pivotal trial for SIEGEL TAVR valve
severe symptomatic aortic stenosissource ↗
Past FDA Catalysts and PDUFA Decisions
How BSX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-02-13 | Aurlumyn (iloprost) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$120M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 57%
Large Pharma(rank 377 of 660)
Percentile Rank
Boston Scientific Corporation faces pipeline headwinds (34/100), with $120M risk-adjusted pipeline value, led by BGC20-0582 in Pediculus Humanus Capitis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BGC20-0582 Small moleculeCompletedNCT00528021 | Pediculus Humanus Capitis | Phase 2 | COMPLETED | 230 | Jun 1, 2008 |
Clinical Trial Results
Readouts, endpoints and source filings for every BSX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter | severely calcified coronary artery disease | 2026-05-19 | freedom from MACE: 93.3%; procedural success rate: 93.7%Read More | FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpointsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| O'Connor Padraig AndrewOfficer (EVP, Global Operations) | Option | 1,171 8,459 held | $0.00 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BSX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.2 % (-60 %) | 63.30 M | 1.48 M | -37.74% ( -898.90 K) |
BSX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BSX ranks across every disease it competes in
Competitive Position is a premium feature
See how BSX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBSX News
BSX▲ +1.4%today
Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
Boston Scientific has appointed Joseph M. Fitzgerald as Executive Vice President and COO, effective January 1, 2027. This new role will see him oversee global operations and business units. The company is also restructuring into three reportable segments to improve decision-making and investment allocation, reflecting its growth ambitions.
Read more →BSXBoston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
Boston Scientific Corporation will participate in the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. CEO Mike Mahoney and CMO Kenneth Stein will engage in a Q&A session. Additionally, the company will hold a conference call on October 28, 2026, to discuss its third-quarter financial results.
Read more →BSXBoston Scientific announces results for second quarter 2026
Boston Scientific reported a strong second quarter in 2026, achieving net sales of $5.442 billion, a 7.5% increase year-over-year. The company also reported a GAAP net income of $907 million, up from $797 million in the previous year. Key growth was noted in the Cardiovascular and MedSurg segments, with significant contributions from various regions. The company remains optimistic about its long-term growth strategy and innovation in medical technologies.
Read more →BSXFRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Boston Scientific's FRACTURE IDE trial for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter has successfully met its primary safety and effectiveness endpoints. The study demonstrated a 93.3% rate of freedom from major adverse cardiac events at 30 days and a 93.7% procedural success rate. These results indicate the catheter's potential in treating patients with severely calcified coronary artery disease.
Read more →BSX▲ +6.2%on this newsshared move
Boston Scientific enters into $2 billion accelerated share repurchase agreement
Boston Scientific has announced a $2 billion accelerated share repurchase agreement with JPMorgan Chase. This initiative is part of a broader $5 billion share repurchase authorization. The ASR is expected to positively impact adjusted earnings per share by $0.02 for the full year 2026. The final settlement of the ASR is anticipated by June 30, 2026.
Read more →BSX▲ +6.2%on this newsshared move
Boston Scientific announces strategic investment in MiRus LLC
Boston Scientific has invested $1.5 billion for a 34% stake in MiRus LLC, focusing on the SIEGEL Balloon Expandable TAVR system. This investment includes an exclusive option to acquire the TAVR technology, which is designed to treat severe aortic stenosis. The SIEGEL valve features a unique rhenium alloy and aims to enhance patient outcomes. MiRus has initiated a pivotal trial to evaluate the valve's safety and effectiveness.
Read more →BSXBoston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results
Boston Scientific Corporation will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026. CEO Mike Mahoney and CMO Janar Sathananthan will engage in a Q&A session. The company will also host a conference call on July 29, 2026, to discuss its second-quarter financial results, with a news release issued beforehand.
Read more →BSXData at Heart Rhythm 2026 highlight key Boston Scientific therapies
Boston Scientific presented positive data at Heart Rhythm 2026, highlighting the effectiveness and safety of its FARAPULSE Pulsed Field Ablation and WATCHMAN LAAC devices. The AVANT GUARD trial showed FARAPULSE PFA's superiority over anti-arrhythmic drugs, while the WATCHMAN FLX Pro achieved high procedural success rates. These findings support the expansion of Boston Scientific's cardiovascular portfolio.
Read more →BSX▲ +9%on this newsshared move
Boston Scientific announces results for first quarter 2026
Boston Scientific reported strong financial results for Q1 2026, with net sales of $5.203 billion, reflecting an 11.6% increase year-over-year. The company also achieved a GAAP net income of $1.341 billion, up from $674 million in the prior year. Key growth segments included cardiovascular and MedSurg, while successful clinical trials were highlighted, including studies on the WATCHMAN FLX device and EKOS system. The company remains focused on its long-term strategy and pipeline advancements.
Read more →BSX▼ -9%on this news
CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
The CHAMPION-AF trial demonstrated that the WATCHMAN FLX device is a viable first-line therapy for stroke risk reduction in patients with non-valvular atrial fibrillation. The study met all primary and secondary endpoints, showing superior safety and efficacy compared to traditional blood thinners. With a 99% procedural success rate, the results may influence future clinical guidelines.
Read more →BSX▼ -9%on this news
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
The HI-PEITHO trial revealed that the EKOS™ Endovascular System significantly outperformed standard anticoagulation therapy in treating intermediate-risk pulmonary embolism. The study showed a 61% reduction in clinical events, with no increase in major bleeding risks. These findings were presented at the ACC.26 and published in The New England Journal of Medicine, marking a potential shift in treatment protocols.
Read more →BSX▼ -9%on this newsshared move
Boston Scientific announces conference call discussing first quarter 2026 results
Boston Scientific Corporation will hold a conference call on April 22, 2026, to discuss its financial results for the first quarter. The call will be hosted by CEO Mike Mahoney and CFO Jon Monson. A news release with the financial results will be issued prior to the call. The event will be available via live webcast and replay.
Read more →BSX▼ -9%on this newsshared move
Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System
Boston Scientific has received FDA 510(k) clearance for its Asurys Fluid Management System, aimed at enhancing irrigation management during endoscopic urologic procedures. This innovative system is designed to maintain fluid flow while managing intrarenal pressure, thus improving patient safety and outcomes. The Asurys System will be integrated with the LithoVue Elite Ureteroscope to further streamline urologic workflows.
Read more →BSXBoston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m. ET / 5:30 p.m. CT to ...
Boston Scientific Corporation will hold an investor event on March 28, 2026, during the 75th Annual Scientific Session of the American College of Cardiology. The event will include discussions on key clinical data presented that day and will be led by prominent medical executives of the company. Investors will have the opportunity to engage through a live webcast, with a replay available shortly after the event concludes.
Read more →BSXBoston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
Boston Scientific Corporation has elected Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. Smith, a seasoned executive with a strong finance background, and Weber, the current CEO of Takeda Pharmaceutical, bring valuable leadership and strategic insight. Their appointments follow the retirements of John Sununu and Yoshiaki Fujimori, who will not seek re-election.
Read more →BSXBoston Scientific to participate in TD Cowen's 46th Annual Health Care Conference
Boston Scientific Corporation will participate in TD Cowen's 46th Annual Health Care Conference on March 3, 2026. CEO Mike Mahoney and CMO Kenneth Stein will engage in a 30-minute Q&A session. A live webcast will be available, along with a replay shortly after the event. This participation highlights Boston Scientific's ongoing commitment to healthcare innovation.
Read more →BSX▼ -17.6%on this news
Boston Scientific announces results for fourth quarter and full year 2025
Boston Scientific reported robust financial results for Q4 and full year 2025, achieving net sales of $5.286 billion in Q4, a 15.9% increase year-over-year. The company's full-year net sales reached $20.074 billion, marking a 19.9% growth. Adjusted EPS also rose, reflecting strong operational performance and a positive outlook for 2026.
Read more →BSXBoston Scientific announces agreement to acquire Penumbra, Inc.
Boston Scientific has entered into a definitive agreement to acquire Penumbra, Inc. for $374 per share, valuing the deal at approximately $14.5 billion. This acquisition aims to enhance Boston Scientific's presence in the cardiovascular sector and address the rising prevalence of vascular diseases. The transaction is expected to be completed in 2026, pending stockholder approval.
Read more →About Boston Scientific Corporation
Headquarters300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA, 01752-1234
BIOPHARMAWATCH ELITE PLUS
Trade the next BSX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime